IO Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IO Biotech and other ETFs, options, and stocks.

About IOBT

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. 

CEO
Mai-Britt Zocca
CEOMai-Britt Zocca
Employees
80
Employees80
Headquarters
Copenhagen, North Denmark
HeadquartersCopenhagen, North Denmark
Founded
2014
Founded2014
Employees
80
Employees80

IOBT Key Statistics

Market cap
39.48M
Market cap39.48M
Price-Earnings ratio
-0.39
Price-Earnings ratio-0.39
Dividend yield
Dividend yield
Average volume
883.27K
Average volume883.27K
High today
$0.5499
High today$0.5499
Low today
$0.48
Low today$0.48
Open price
$0.52
Open price$0.52
Volume
521.07K
Volume521.07K
52 Week high
$2.79
52 Week high$2.79
52 Week low
$0.3234
52 Week low$0.3234

Stock Snapshot

As of today, IO Biotech(IOBT) shares are valued at $0.51. The company's market cap stands at 39.48M, with a P/E ratio of -0.39.

As of 2026-01-14, IO Biotech(IOBT) stock has fluctuated between $0.48 and $0.55. The current price stands at $0.51, placing the stock +6.5% above today's low and -7.0% off the high.

The IO Biotech(IOBT)'s current trading volume is 521.07K, compared to an average daily volume of 883.27K.

During the past year, IO Biotech(IOBT) stock moved between $0.32 at its lowest and $2.79 at its peak.

During the past year, IO Biotech(IOBT) stock moved between $0.32 at its lowest and $2.79 at its peak.

People also own

Based on the portfolios of people who own IOBT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .